Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 21;15(1):172.
doi: 10.1038/s41408-025-01376-9.

The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis

Maria Chiara Finazzi #  1 , Silvia Salmoiraghi #  2 , Francesca Valsecchi  2 , Chiara Pavoni  2 , Clara Belotti  2 , Anna Grassi  2 , Alessandra Algarotti  2 , Federico Lussana  2   3 , Benedetta Rambaldi  2 , Giuliana Rizzuto  2 , Gianluca Cavallaro  2 , Annalisa Condorelli  2 , Marta Bellini  2 , Orietta Spinelli  2 , Alessandro Rambaldi  2   3
Affiliations

The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis

Maria Chiara Finazzi et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethical approval: All methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the Ethics Committee at the ASST Papa Giovanni XXIII, Bergamo, under reference number 1029. Informed consent: Informed consent was obtained from all participants before their inclusion in the study.

Figures

Fig. 1
Fig. 1. Outcome of patients according to the pre-transplant number of high molecular risk mutations.
Overall survival (A), progression-free survival (B), and non-relapse mortality (C). (Blue continous line: none or only one HMR mutation, red dotted line: 2 or more HMR mutations).
See this image and copyright information in PMC

References

    1. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861–9. - PubMed
    1. Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS701 version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769–70. - PubMed
    1. Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz MM, et al. Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23:1095–101. - PubMed
    1. Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, et al. Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis. Biol Blood Marrow Transplant. 2019;25:1142–51 - PMC - PubMed
    1. Gagelmann N, Salit RB, Schroeder T, Badbaran A, Rautenberg C, Panagiota V, et al. High molecular and cytogenetic risk in myelofibrosis does not benefit from higher intensity conditioning before hematopoietic cell transplantation: an international collaborative analysis. Hemasphere. 2022;6:E784 - PMC - PubMed

LinkOut - more resources